Amber L Watters1,2, Shane Cope1, Meir N Keller1, Mariela Padilla3, Reyes Enciso4. 1. Master of Science Program in Orofacial Pain and Oral Medicine, Herman Ostrow School of Dentistry of University of Southern California, Los Angeles, California. 2. Oral Oncology, Providence Cancer Institute, Robert W. Franz Cancer Center, Portland, Oregon. 3. Division of Periodontology, Diagnostic Sciences & Dental Hygiene, Herman Ostrow School of Dentistry of University of Southern California, Los Angeles, California. 4. Division of Dental Public Health and Pediatric Dentistry, Herman Ostrow School of Dentistry of University of Southern California, Los Angeles, CA.
Abstract
BACKGROUND: The purpose of this systematic review and meta-analysis was to determine the prevalence of trismus in patients with head and neck cancer. METHODS: Four electronic databases were searched: Cochrane Library, MEDLINE, EMBASE, and Web of Science up to April 2018. Level of evidence was assessed based on Oxford Centre for Evidence-based Medicine. Publications were restricted to prospective cohort studies (n = 15), randomized clinical trials (n = 3), and cross-sectional studies (n = 5) reporting on trismus as mouth maximum opening less than or equal to 35 mm in the English language. RESULTS: A total of 636 abstracts were reviewed for inclusion. Twenty-three studies were included in qualitative analysis and 15 studies in meta-analysis. The results included 2786 patients with head and neck cancer treated with surgery, radiotherapy, and/or chemotherapy either alone or in combination. Based on meta-analyses, the weighted average prevalence of trismus increased from 17.3% at baseline (95% confidence interval [CI], 10.8%-26.5%) to a peak of 44.1% at 6 months (95% CI, 36.7%-51.8%) and decreased to 32.1% at 12 months (95% CI, 27.2%-37.4%) and continued in average 32.6% at 3-10 years (95% CI, 22.0%-45.3%). CONCLUSIONS: Having a primary site of the oral cavity or oropharynx was associated with a higher risk for developing trismus based on individual studies. Prospective cohort studies or randomized controlled trials with multiple objective trismus measurements, evaluation of disease characteristics, and treatment variables are needed to further investigate the prevalence of trismus secondary to head and neck cancer treatment.
BACKGROUND: The purpose of this systematic review and meta-analysis was to determine the prevalence of trismus in patients with head and neck cancer. METHODS: Four electronic databases were searched: Cochrane Library, MEDLINE, EMBASE, and Web of Science up to April 2018. Level of evidence was assessed based on Oxford Centre for Evidence-based Medicine. Publications were restricted to prospective cohort studies (n = 15), randomized clinical trials (n = 3), and cross-sectional studies (n = 5) reporting on trismus as mouth maximum opening less than or equal to 35 mm in the English language. RESULTS: A total of 636 abstracts were reviewed for inclusion. Twenty-three studies were included in qualitative analysis and 15 studies in meta-analysis. The results included 2786 patients with head and neck cancer treated with surgery, radiotherapy, and/or chemotherapy either alone or in combination. Based on meta-analyses, the weighted average prevalence of trismus increased from 17.3% at baseline (95% confidence interval [CI], 10.8%-26.5%) to a peak of 44.1% at 6 months (95% CI, 36.7%-51.8%) and decreased to 32.1% at 12 months (95% CI, 27.2%-37.4%) and continued in average 32.6% at 3-10 years (95% CI, 22.0%-45.3%). CONCLUSIONS: Having a primary site of the oral cavity or oropharynx was associated with a higher risk for developing trismus based on individual studies. Prospective cohort studies or randomized controlled trials with multiple objective trismus measurements, evaluation of disease characteristics, and treatment variables are needed to further investigate the prevalence of trismus secondary to head and neck cancer treatment.
Authors: À Roselló; R Albuquerque; X Roselló-Llabrés; A Marí-Roig; A Estrugo-Devesa; J López-López Journal: Med Oral Patol Oral Cir Bucal Date: 2020-09-01
Authors: Maximiliaan Smeets; Tomas-Marijn Croonenborghs; Jeroen Van Dessel; Constantinus Politis; Reinhilde Jacobs; Michel Bila Journal: Front Oral Health Date: 2022-01-21
Authors: Richard C Cardoso; Mona Kamal; Jhankruti Zaveri; Mark S Chambers; G Brandon Gunn; Clifton D Fuller; Stephen Y Lai; Frank E Mott; Holly McMillan; Katherine A Hutcheson Journal: Support Care Cancer Date: 2020-08-11 Impact factor: 3.603
Authors: Rebecca T Karsten; Najiba Chargi; Lisette van der Molen; Rob J J H van Son; Remco de Bree; Abrahim Al-Mamgani; Jan P de Boer; Frans J M Hilgers; Michiel W M van den Brekel; Ludi E Smeele; Martijn M Stuiver Journal: Eur Arch Otorhinolaryngol Date: 2021-05-27 Impact factor: 2.503